ImmunityBio, Inc. - Common Stock (IBRX)

In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise to many retail investors, especially considering that the drop coincided with a significant

Investors are looking at earnings from Abercrombie & Fitch, Broadcom and Okta on Wednesday.

To address the BCG shortage, ImmunityBio highlighted its recombinant BCG program, with 580 patients enrolled across about 100 clinical sites.

The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.

Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda.

Founder Patrick Soon-Shiong is set for back-to-back prime-time interviews on Fox News and NewsNation on Friday.

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged.

The filing comes ahead of ImmunityBio’s participation in the ASCO Genitourinary Cancers Symposium.

Traders debated whether Trump could reference cancer priorities or FDA reform, with some betting a mention could spark another leg higher for IBRX.

ImmunityBio outlined a three-year plan to position Anktiva as a backbone immunotherapy, advancing more than 30 trials across 10 tumor types.

On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global expansion.

ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.

Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.

The chairman pointed to upcoming updates on IL-15’s long-studied role in cancer immunotherapy.

ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time.

Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume.

Traders are closely watching positioning, as short interest hit a record 13.7% of the free float amid a jump in retail activity on Stocktwits this week.

As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire founder, Dr. Patrick Soon-Shiong, the company has rapidly evolved into a commercial-stage powerhouse in the immunotherapy landscape. ImmunityBio is currently in focus due to [...]

The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

The standoff ended when the EU granted conditional approval, sending shares up 42% on Wednesday.